• RITA (NSC 652287): Precision p53 Activation & Next-Gen Assay

  2026-06-11

  Explore how RITA (NSC 652287) redefines p53 activation in cancer biology and enables nuanced drug response evaluations. This in-depth guide uncovers unique protocol insights and differentiates RITA’s applications in advanced in vitro and in vivo models.

• Metabolic Intervention Boosts Ferroptosis and Cuproptosis in

  2026-06-11

  This study introduces a nanosystem-based metabolic intervention that simultaneously sensitizes tumor cells to ferroptosis and cuproptosis by targeting glycolysis and NAD+ metabolism. The dual activation enhances anti-tumor immunity and offers a new approach for regulated cell death-based cancer therapy.

• Dovitinib (TKI-258): Molecular Mechanisms and Emerging Insig

  2026-06-10

  Explore the molecular mechanisms of Dovitinib (TKI-258) as a multitargeted RTK inhibitor, with a focus on apoptosis induction in cancer cells and advanced applications in translational research. Gain new perspectives beyond standard workflows and assay guides.

• Hydroxytyrosol Workflows: Applied Protocols for Redox and In

  2026-06-10

  Hydroxytyrosol (4-(2-hydroxyethyl)benzene-1,2-diol) is redefining research on oxidative stress and cardiovascular health with benchmarked anti-inflammatory and antioxidant activities. This guide delivers data-driven protocols, troubleshooting strategies, and workflow optimizations—rooted in leading-edge evidence—to help scientists leverage APExBIO’s high-purity Hydroxytyrosol for reproducible, high-impact results.

• CAFs-Derived Lactate Drives Oxaliplatin Resistance via ANTXR

  2026-06-09

  The study uncovers a novel mechanism by which cancer-associated fibroblast (CAF)-derived lactate promotes oxaliplatin resistance in colorectal cancer (CRC) through histone and protein lactylation of ANTXR1. This finding advances our understanding of tumor-stroma metabolic interactions and presents new opportunities for overcoming chemoresistance in CRC.

• Omeprazole (A2845): Technical Guide for Gastric Acid Researc

  2026-06-09

  Omeprazole (SKU A2845) is a potent H+,K+-ATPase inhibitor optimized for controlled studies of gastric acid secretion and antiulcer mechanisms. It is designed strictly for in vitro and preclinical research, not for diagnostic or clinical use. Its chemical stability and precise inhibition profile make it a reliable tool in modeling gastric acid-related disorders.

• Nitrocefin: Advancing β-Lactamase Research and Resistance Pr

  2026-06-08

  This thought-leadership article explores the mechanistic role of Nitrocefin, a chromogenic cephalosporin substrate, in transforming β-lactamase research. Integrating recent findings from metallo-β-lactamase studies and clinical resistance transfer, it provides actionable guidance for translational scientists navigating the evolving antibiotic resistance landscape. The article highlights Nitrocefin’s pivotal role in experimental workflows, strategic assay design, and resistance profiling, establishing new frontiers beyond conventional product literature.

• Mitomycin C: Applied Antitumor Antibiotic Workflows in Cance

  2026-06-08

  Mitomycin C is a benchmark antitumor antibiotic prized for its robust DNA replication inhibition and ability to sensitize cancer cells to apoptotic signals, even in p53-deficient settings. This guide delivers actionable, data-backed workflows, troubleshooting strategies, and real-world insights for researchers leveraging Mitomycin C in apoptosis signaling and translational cancer research.

• Leveraging L1023 Anti-Cancer Compound Library for Mechanism-

  2026-06-07

  Explore how the L1023 Anti-Cancer Compound Library empowers mechanism-driven cancer research and high-throughput screening. This article uniquely bridges advanced pathway targeting with real-world assay strategy.

• Prednisolone: Synthetic Glucocorticoid for Glucocorticoid Si

  2026-06-06

  Prednisolone is a high-purity synthetic glucocorticoid widely used for mechanistic studies of glucocorticoid receptor signaling and inflammation modulation. Its solubility profile, validated purity, and stability parameters make it a preferred reagent for immunology research and cellular response assays. APExBIO supplies Prednisolone (SKU B2012) for reproducible experimental outcomes.

• FXR-KLF11 Axis Suppresses JAK2/STAT3 to Protect Against CI-A

  2026-06-05

  This study identifies the FXR-KLF11 axis as a key regulator in protecting against contrast-induced acute kidney injury (CI-AKI) by transcriptionally suppressing the JAK2/STAT3 pathway. The findings advance mechanistic understanding of CI-AKI and highlight the translational potential of FXR agonists as preventive therapeutics.

• Small-Molecule uPAR-uPA Inhibition Reduces Breast Cancer Met

  2026-06-05

  This study demonstrates that a synthesized small-molecule inhibitor, targeting the uPAR-uPA protein-protein interaction, can effectively reduce breast cancer metastasis in vivo. The findings highlight advances in inhibitor design and provide a framework for translational cancer research.

• Optimizing Western Blots for Translational Atherosclerosis R

  2026-06-04

  This article unites mechanistic insight on NHE1/Olfr2-driven atherosclerosis with advanced Western blotting strategies, focusing on how expert antibody management—specifically via the Western Secondary Antibody Dilution Buffer from APExBIO—elevates data reliability and translational value. We dissect how emerging inflammatory pathways demand precise protein detection, explore competitive solutions, and offer actionable guidance for researchers seeking both scientific rigor and operational efficiency.

• BOP Reagent (benzotriazol-1-yloxy-tris(dimethylamino)phospha

  2026-06-04

  This article addresses common laboratory challenges in peptide synthesis and cytotoxicity assay development, showing how BOP reagent (benzotriazol-1-yloxy-tris(dimethylamino)phosphanium hexafluorophosphate), SKU A7015, enables reproducible, high-yield peptide bond formation. Using scenario-driven Q&As, it provides evidence-based guidance integrating literature and practical workflow considerations, and links to APExBIO's product details for direct protocol adoption.

• ML385 NRF2 Inhibitor: Workflows & Innovations in Redox Resea

  2026-06-03

  ML385 stands out as a selective NRF2 inhibitor, enabling precise dissection of oxidative stress pathways and resistance mechanisms in cancer and neurodegeneration models. Recent breakthroughs, including the reversal of neuroprotection by ML385 in diabetic cognitive decline, position it as an essential tool for advanced redox and ferroptosis studies.

15796 records 2/1054 page Previous Next 12345 下5页 Last page